<VariationArchive VariationID="938833" VariationName="NM_000152.5(GAA):c.2432del (p.Leu811fs)" VariationType="Deletion" Accession="VCV000938833" Version="14" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-03-30" DateCreated="2020-07-16" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="938293" VariationID="938833">
      <GeneList>
        <Gene Symbol="GAA" FullName="alpha glucosidase" GeneID="2548" HGNC_ID="HGNC:4065" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="80101581" stop="80119881" display_start="80101581" display_stop="80119881" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NW_025791802.1" start="126287" stop="144587" display_start="126287" display_stop="144587" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="78075354" stop="78093678" display_start="78075354" display_stop="78093678" Strand="+" />
          </Location>
          <OMIM>606800</OMIM>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000152.5(GAA):c.2432del (p.Leu811fs)</Name>
      <CanonicalSPDI>NC_000017.11:80117699:T:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="80117700" stop="80117700" display_start="80117700" display_stop="80117700" variantLength="1" positionVCF="80117699" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="78091499" stop="78091499" display_start="78091499" display_stop="78091499" variantLength="1" positionVCF="78091498" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>L811fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_673" sequenceAccession="LRG_673">
            <Expression>LRG_673:g.21145del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_673t1" sequenceAccession="LRG_673t1">
            <Expression>LRG_673t1:c.2432del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.78091499del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.78091499del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.80117700del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.80117700del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009822.1" sequenceAccession="NG_009822" sequenceVersion="1" change="g.21145del">
            <Expression>NG_009822.1:g.21145del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000152.5" sequenceAccession="NM_000152" sequenceVersion="5" change="c.2432del" MANESelect="true">
            <Expression>NM_000152.5:c.2432del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000143.2" sequenceAccession="NP_000143" sequenceVersion="2" change="p.Leu811fs">
            <Expression>NP_000143.2:p.Leu811fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079803.3" sequenceAccession="NM_001079803" sequenceVersion="3" change="c.2432del">
            <Expression>NM_001079803.3:c.2432del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073271.1" sequenceAccession="NP_001073271" sequenceVersion="1" change="p.Leu811fs">
            <Expression>NP_001073271.1:p.Leu811fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079804.3" sequenceAccession="NM_001079804" sequenceVersion="3" change="c.2432del">
            <Expression>NM_001079804.3:c.2432del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073272.1" sequenceAccession="NP_001073272" sequenceVersion="1" change="p.Leu811fs">
            <Expression>NP_001073272.1:p.Leu811fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000152.4" sequenceAccession="NM_000152" sequenceVersion="4" change="c.2432delT">
            <Expression>NM_000152.4:c.2432delT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="766560578" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00000" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00001" Source="Exome Aggregation Consortium (ExAC)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000152.5(GAA):c.2432del (p.Leu811fs) AND Glycogen storage disease, type II" Accession="RCV001208130" Version="12">
        <ClassifiedConditionList TraitSetID="1104">
          <ClassifiedCondition DB="MedGen" ID="C0017921">Glycogen storage disease, type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-07-25" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-25" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2020-07-16" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16433701</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18425781</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18429042</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22252923</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24269976</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31606152</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/afe7d150-0db1-403c-8534-d2732d22a789</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="1104" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1936" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Glucosidase acid-1,4-alpha deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen Storage Disease Type II (Pompe Disease)</ElementValue>
                <XRef ID="NBK1261" DB="GeneReviews" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACID ALPHA-GLUCOSIDASE DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLYCOGENOSIS, GENERALIZED, CARDIAC FORM</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD II</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POMPE DISEASE</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid maltase deficiency disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Aglucosidase alfa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-1,4-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardiomegalia glycogenica diffusa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of alpha-glucosidase</ElementValue>
                <XRef ID="124462004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of lysosomal alpha-glucosidase</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Glycogen storage disease, type II</ElementValue>
                <XRef ID="Glycogen+Storage+Disease+Type+2/3122" DB="Genetic Alliance" />
                <XRef ID="237967002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AMD</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">GSD2</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2503" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5714" />
                <XRef ID="5714" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Pompe disease is classified by age of onset, organ involvement, severity, and rate of progression. Infantile-onset Pompe disease (IOPD; individuals with onset before age 12 months with cardiomyopathy) may be apparent in utero but more typically onset is at the median age of four months with hypotonia, generalized muscle weakness, feeding difficulties, failure to thrive, respiratory distress, and hypertrophic cardiomyopathy. Without treatment by enzyme replacement therapy (ERT), IOPD commonly results in death by age two years from progressive left ventricular outflow obstruction and respiratory insufficiency. Late-onset Pompe disease (LOPD; including: (a) individuals with onset before age 12 months without cardiomyopathy; and (b) all individuals with onset after age 12 months) is characterized by proximal muscle weakness and respiratory insufficiency; clinically significant cardiac involvement is uncommon.</Attribute>
                <XRef ID="NBK1261" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301438</ID>
                <ID Source="BookShelf">NBK1261</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3110959</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Pompe.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet- Pompe Disease (Glycogen Storage Disease type II), 2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Pompe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Pompe disease: acid alpha-glucosidase deficiency, 2022</CitationText>
              </Citation>
              <XRef ID="365" DB="Orphanet" />
              <XRef ID="C0017921" DB="MedGen" />
              <XRef ID="MONDO:0009290" DB="MONDO" />
              <XRef Type="MIM" ID="232300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2805148" SubmissionDate="2020-03-09" DateLastUpdated="2022-02-02" DateCreated="2020-07-19">
        <ClinVarSubmissionID localKey="afe7d150-0db1-403c-8534-d2732d22a789|Orphanet:ORPHA365" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001422737" DateUpdated="2022-02-02" DateCreated="2020-07-19" Type="SCV" Version="2" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16433701</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18429042</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24269976</ID>
          </Citation>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/afe7d150-0db1-403c-8534-d2732d22a789</URL>
          </Citation>
          <Comment>The p.Leu811ArgfsTer37 variant in GAA has been reported in at least 5 individuals with glycogen storage disease, segregated with disease in 2 affected relatives from 1 family (PMID: 25763511, 24269976, 16433701, 22252923, 18429042), and has been identified in 0.010% (1/9914) of Ashkenazi Jewish chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs766560578). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro functional studies have showed patients with the variant to be CRIM-negative (PMID: 25763511, 22252923). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at position 811 and leads to a premature termination codon 37 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the GAA gene is an established disease mechanism in autosomal recessive glycogen storage disease. The phenotype of an individual homozygous for this variant is highly specific for glycogen storage disease based on null GAA enzyme activity in lymphocytes, consistent with disease (PMID: 16433701). Additionally, the presence of this variant in combination with the reported pathogenic variant (p.Asp404Asn) and in an individual with glycogen storage disease increases the likelihood that the p.Leu811ArgfsTer37 variant is pathogenic (PMID: 22538254, 29122469, 29205646, 25687635, 22658377, 23787031, 26497565, 16433701, 243843240). In summary, this variant meets criteria to be classified as pathogenic for glycogen storage disease in an autosomal recessive manner based on the prediction that it causes loss of function, and its presence in combination with another pathogenic variant in an affected individual. ACMG/AMP Criteria applied: PVS1, PM3, PM2, PP4 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_001079804.2:c.2432del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.11:g.80117700del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA365" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6906750</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4081835" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000152.5:c.2432del|Glycogen storage disease type II" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002092141" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-02-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000152.5:c.2432del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Glycogen storage disease type II</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5001425" SubmissionDate="2022-07-29" DateLastUpdated="2022-08-08" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="NM_000152.4:c.2432delT|MedGen:C0017921" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002556139" DateUpdated="2022-08-08" DateCreated="2022-08-08" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22252923</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18429042</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16433701</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31606152</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24269976</ID>
          </Citation>
          <Comment>Variant summary: GAA c.2432delT (p.Leu811ArgfsX37) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 247066 control chromosomes (gnomAD). c.2432delT has been reported in the literature in multiple individuals affected with Glycogen Storage Disease, Type 2 (Pompe Disease), including at least two cases where it has been detected in trans with a pathogenic variant (e.g. Amartino_2006, Pittis_2008, Bali_2012, Fu_2014, Gupta_2020). These data indicate that the variant is very likely to be associated with disease. The variant is also commonly observed in CRIM-negative Pompe Disease patients, indicated by an absense of protein detected by western blot (e.g. Bali_2012, Gupta_2020). Three assessments for this variant have been submitted to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000152.4:c.2432delT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017921" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11876943</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2714274" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="4946436|MedGen:C0017921" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001379505" DateUpdated="2024-02-14" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">18425781</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22252923</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16433701</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18429042</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24269976</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Leu811Argfs*37) in the GAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). This variant is present in population databases (rs766560578, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with glycogen storage disease type II (PMID: 16433701, 18429042, 24269976). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 938833). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.78091499del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017921" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5001425" TraitType="Disease" MappingType="XRef" MappingValue="C0017921" MappingRef="MedGen">
        <MedGen CUI="C0017921" Name="Glycogen storage disease, type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2805148" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA365" MappingRef="Orphanet">
        <MedGen CUI="C0017921" Name="Glycogen storage disease, type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4081835" TraitType="Disease" MappingType="Name" MappingValue="Glycogen storage disease type II" MappingRef="Preferred">
        <MedGen CUI="C0017921" Name="Glycogen storage disease, type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2714274" TraitType="Disease" MappingType="XRef" MappingValue="C0017921" MappingRef="MedGen">
        <MedGen CUI="C0017921" Name="Glycogen storage disease, type II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

